Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

umcos newcombe pty limited - sucrose octa-acetate; denatonium benzoate; aluminium ammonium sulfate - soluble powder - sucrose octa-acetate carbohydrate derivative active 1.5 g/kg; denatonium benzoate carbamate active 0.1 g/kg; aluminium ammonium sulfate mineral-aluminium active 997.3 g/kg - repellent - dogs etc - around established trees | base of building wall, fence or rockwork | bed - plant - general | building | bulb and corm - prior t - bird | cat | dog | mouse - mus spp. | possum | rabbit | rat | rodent, rat or mouse | wallaby - see label | wildlife | bird | black rat/mouse | brown rat/mouse | echidna | fox | kangaroo | mouse | possum | rabbit | rat | refer to label | rodent | roof rat | wallaby | wombat

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - ammonium sulphate - granular formulation - ammonium sulphate ammonium active 980.0 g/kg - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - improve performance | tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank | under adverse environmental co

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

titan ag pty ltd - ammonium sulphate - granular formulation - ammonium sulphate ammonium active 980.0 g/kg - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - improve performance | tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank | under adverse environmental co

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

nutrien ag solutions limited - ammonium sulphate - granular formulation - ammonium sulphate ammonium active 980.0 g/kg - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - improve performance | tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank | under adverse environmental co

Австралия - английский - APVMA (Australian Pesticides and Veterinary Medicines Authority)

wilchem pty ltd - ammonium sulfate - granular formulation - ammonium sulfate ammonium active 980.0 g/kg - adjuvant - herbicide additive | activator | penetrant | post emergent herbicide | spreading adjuvant | surfactant | wetting agent - improve performance | tank mixing | additive | agricultural chemical | herbicide | minimise antagonism | spray tank | under adverse environmental co

Новая Зеландия - английский - Ministry for Primary Industries

envirofume limited - aluminium phosphide - aluminium phosphide 570 g/kg - insecticide

Соединенные Штаты - английский - NLM (National Library of Medicine)

novel laboratories, inc. - dextroamphetamine sulfate (unii: jj768o327n) (dextroamphetamine - unii:tz47u051fi) - dextroamphetamine sulfate 5 mg - dextroamphetamine sulfate tablets usp are indicated for: 1.         narcolepsy. 2.         attention deficit disorder with hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. the diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. nonlocalizing (soft) neurological signs, learning disability, and abnormal eeg may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, known hypersensitivity or idiosyncrasy

Австралия - английский - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - conjugated estrogens, quantity: 0.45 mg; bazedoxifene acetate, quantity: 22.56 mg (equivalent: bazedoxifene, qty 20 mg) - tablet, modified release - excipient ingredients: lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; macrogol 400; magnesium stearate; sucrose palmitate; ascorbic acid; powdered cellulose; calcium phosphate; sucrose; propylene glycol; purified water; isopropyl alcohol; iron oxide black; titanium dioxide; iron oxide red; polydextrose; povidone; hyetellose; maltitol solution; poloxamer - duavive is indicated for treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus.,- duavive should be used for the shortest duration consistent with treatment goals and risks for the individual woman.,- experience in women older than 65 years is limited.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - lamivudine, quantity: 300 mg; abacavir sulfate, quantity: 702.76 mg (equivalent: abacavir, qty 600 mg) - tablet, film coated - excipient ingredients: hypromellose; titanium dioxide; sunset yellow fcf aluminium lake; macrogol 8000; croscarmellose sodium; magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose - abacavir and lamivudine combination tablets are a combination of two nucleoside analogues (abacavir and lamivudine). ,abacavir and lamivudine combination tablets are indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and adolescents from 12 years of age.

Австралия - английский - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - clopidogrel hydrogen sulfate, quantity: 391.5 mg (equivalent: clopidogrel, qty 300 mg) - tablet, film coated - excipient ingredients: hydrogenated castor oil; hyprolose; microcrystalline cellulose; mannitol; macrogol 6000; carnauba wax; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide red - prevention of vascular ischaemia associated with atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with a history of symptomatic atherosclerotic disease. acute coronary syndrome. plavix is indicated in combination with aspirin for patients with: unstable angina or non-st-elevation myocardial infarction in order to prevent early and long-term atherothrombotic events (myocardial infarction, stroke, vascular death or refractory ischaemia). plavix is indicated for the treatment of acute coronary syndrome whether or not patients undergo cardiac revascularisation (surgical or pci, with or without stent). st-segment elevation acute myocardial infarction in order to prevent atherothrombotic events. in this population, plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke in medically treated patients eligible for thrombolytic therapy.